Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
暂无分享,去创建一个
Seth M Cohen | Seth M. Cohen | Jessica L. Fullagar | Jennifer A Jacobsen | Melissa T Miller | Jessica L Fullagar | Jennifer A. Jacobsen | M. Miller | Melissa T Miller
[1] Andrew J. Woodhead,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[2] Hwan-Suck Chung,et al. Naturally occurring tyrosinase inhibitors: mechanism and applications in skin health, cosmetics and agriculture industries , 2007, Phytotherapy research : PTR.
[3] R. Sindelar,et al. Hydroxamic acids as pharmacological agents. , 2002, Current medicinal chemistry.
[4] Sina Bavari,et al. The evolving field of biodefence: therapeutic developments and diagnostics , 2005, Nature Reviews Drug Discovery.
[5] M. Giorgi,et al. Binding of 2-hydroxypyridine-N-oxide on dicopper(II) centers: insights into tyrosinase inhibition mechanism by transition-state analogs. , 2009, Inorganic chemistry.
[6] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[7] M. Suresh,et al. Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. , 2009, Journal of medicinal chemistry.
[8] Seth M. Cohen,et al. A Macrophage Cell Model for Selective Metalloproteinase Inhibitor Design , 2008, Chembiochem : a European journal of chemical biology.
[9] Development of integrase inhibitors for treatment of AIDS: an overview. , 2007, European journal of medicinal chemistry.
[10] A. Strongin,et al. Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. , 2006, Journal of medicinal chemistry.
[11] Richard H. Henchman,et al. From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery. , 2003, Angewandte Chemie.
[12] L. Kotra,et al. Structural insight into the binding motifs for the calcium ion and the non-catalytic zinc in matrix metalloproteases. , 1998, Bioorganic & medicinal chemistry letters.
[13] Seth M. Cohen,et al. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. , 2004, Journal of the American Chemical Society.
[14] J Andrew McCammon,et al. Potent, selective pyrone-based inhibitors of stromelysin-1. , 2005, Journal of the American Chemical Society.
[15] Andrew R Leach,et al. Fragment screening: an introduction. , 2006, Molecular bioSystems.
[16] Raphael Nudelman,et al. Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis , 2008, Nature Clinical Practice Rheumatology.
[17] Synthesis and biological evaluation of 1-(benzenesulfonamido)-2-[5-(N-hydroxypyridin-2(1H)-one)]acetylene regioisomers: a novel class of 5-lipoxygenase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[18] Seth M. Cohen,et al. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. , 2003, Inorganic chemistry.
[19] C. Supuran,et al. Design of zinc binding functions for carbonic anhydrase inhibitors. , 2008, Current pharmaceutical design.
[20] Seth M. Cohen,et al. Addressing lead toxicity: complexation of lead(II) with thiopyrone and hydroxypyridinethione O,S mixed chelators. , 2004, Inorganic chemistry.
[21] Seth M. Cohen,et al. A bioinorganic perspective on matrix metalloproteinase inhibition. , 2004, Current topics in medicinal chemistry.
[22] S. Yao,et al. In situ "click" assembly of small molecule matrix metalloprotease inhibitors containing zinc-chelating groups. , 2008, Organic letters.
[23] Susanne Nyström,et al. Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. , 2008, Journal of medicinal chemistry.
[24] Seth M. Cohen,et al. Efficient synthesis of 5-amido-3-hydroxy-4-pyrones as inhibitors of matrix metalloproteinases. , 2007, Organic letters.
[25] Seth M. Cohen,et al. Evaluation and Binding‐Mode Prediction of Thiopyrone‐Based Inhibitors of Anthrax Lethal Factor , 2006, ChemMedChem.
[26] Karl Edman,et al. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. , 2008, Journal of medicinal chemistry.
[27] Takayoshi Suzuki,et al. Rational design of non-hydroxamate histone deacetylase inhibitors. , 2006, Mini reviews in medicinal chemistry.
[28] Y. Wan,et al. 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. , 2008, Bioorganic & medicinal chemistry.
[29] R. Hider,et al. Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values. , 2001, Bioorganic & medicinal chemistry.
[30] Petra Schneider,et al. Scaffold‐Hopping Cascade Yields Potent Inhibitors of 5‐Lipoxygenase , 2008, ChemMedChem.
[31] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[32] M. Uttamchandani,et al. Rapid assembly of matrix metalloprotease inhibitors using click chemistry. , 2006, Organic letters.
[33] W. Denny,et al. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. , 2009, Journal of medicinal chemistry.
[34] Maria João Ramos,et al. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. , 2008, Current medicinal chemistry.
[35] P. Margolis,et al. Targeting metalloenzymes: a strategy that works. , 2003, Current opinion in pharmacology.
[36] P. Sampson,et al. Methionine in and out of proteins: targets for drug design. , 2002, Current medicinal chemistry.
[37] N. Smit,et al. The Hunt for Natural Skin Whitening Agents , 2009, International journal of molecular sciences.
[38] R. Hider,et al. Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values. , 1999, Journal of medicinal chemistry.
[39] Seth M. Cohen,et al. From Sensors to Silencers: Quinoline- and Benzimidazole-Sulfonamides as Inhibitors for Zinc Proteases , 2010, Journal of the American Chemical Society.
[40] R. Hider,et al. The inhibition of tyrosinase by pyridinones. , 1989, The Biochemical journal.
[41] L. Wackett,et al. Atrazine chlorohydrolase from Pseudomonas sp. strain ADP is a metalloenzyme. , 2002, Biochemistry.
[42] P. Ascenzi,et al. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. , 2008, Current medicinal chemistry.
[43] D. Hupe,et al. A Rationalization of the Acidic pH Dependence for Stromelysin-1 (Matrix Metalloproteinase-3) Catalysis and Inhibition* , 2000, The Journal of Biological Chemistry.
[44] Seth M. Cohen,et al. Elucidating drug-metalloprotein interactions with tris(pyrazolyl)borate model complexes. , 2002, Inorganic chemistry.
[45] Yan Guo,et al. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. , 2002, Journal of medicinal chemistry.
[46] R. Bhatnagar,et al. Anthrax Toxin , 2001, Critical reviews in microbiology.
[47] D. Hazuda,et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.
[48] Lewis C Cantley,et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor , 2004, Nature Structural &Molecular Biology.
[49] Seth M. Cohen,et al. Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity , 2006, JBIC Journal of Biological Inorganic Chemistry.
[50] F. García-Carmona,et al. 4-Substituted resorcinols (sulfite alternatives) as slow-binding inhibitors of tyrosinase catecholase activity , 1997 .
[51] F. Leroux,et al. Synthesis of a 200-member library of squaric acid N-hydroxylamide amides. , 2008, Bioorganic & medicinal chemistry letters.
[52] Yuchen Cao,et al. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. , 2009, Bioorganic & medicinal chemistry letters.
[53] Seth M. Cohen,et al. Metal complexes of the trans-influencing ligand thiomaltol. , 2003, Inorganic chemistry.
[54] J H Musser,et al. Synthesis and antiallergic activities of 1,3-oxazolo[4,5-h]quinolines. , 1985, Journal of medicinal chemistry.
[55] Jean M. Severin,et al. Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .
[56] A. Gearing,et al. Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.
[57] P. Dunkel,et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target. , 2008, Current medicinal chemistry.
[58] Y. Yen,et al. Ribonucleotide reductase inhibitors and future drug design. , 2006, Current cancer drug targets.
[59] Seth M Cohen,et al. Zinc‐Binding Groups Modulate Selective Inhibition of MMPs , 2008, ChemMedChem.
[60] E. Sturrock,et al. Inhibition of zinc metallopeptidases in cardiovascular disease--from unity to trinity, or duality? , 2009, Current pharmaceutical design.
[61] L. Bastide,et al. Progress in targeting bacterial transcription. , 2007, Drug discovery today.
[62] D Job,et al. The crystal structure of plant acetohydroxy acid isomeroreductase complexed with NADPH, two magnesium ions and a herbicidal transition state analog determined at 1.65 Å resolution , 1997, The EMBO journal.
[63] S. Meroueh,et al. Quest for selectivity in inhibition of matrix metalloproteinases. , 2004, Current topics in medicinal chemistry.
[64] A. Mai,et al. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. , 2009, Current pharmaceutical design.
[65] C. H. Jarboe,et al. 2-Pyrones. XIX. 3-Hydroxy-2-pyrone1 and 4-Arylhydrazono-2,3-pyranones , 1956 .
[66] Seth M Cohen,et al. A new role for old ligands: discerning chelators for zinc metalloproteinases. , 2006, Journal of the American Chemical Society.
[67] Seth M Cohen,et al. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. , 2010, Biochimica et biophysica acta.
[68] Yi Lu,et al. Metalloprotein and metallo-DNA/RNAzyme design: current approaches, success measures, and future challenges. , 2006, Inorganic chemistry.
[69] M. Pellecchia,et al. Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors. , 2009, Bioorganic & medicinal chemistry.
[70] A. Gearing,et al. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors , 1999 .
[71] C. Fierke,et al. Zinc hydrolases: the mechanisms of zinc-dependent deacetylases. , 2005, Archives of biochemistry and biophysics.
[72] Seth M. Cohen,et al. Chelator Fragment Libraries for Targeting Metalloproteinases , 2010, ChemMedChem.
[73] G. Cristalli,et al. Adenosine deaminase: Functional implications and different classes of inhibitors , 2001, Medicinal research reviews.